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ABSTRACT 
Objective: The objective of the present study was to develop and validate a novel reverse phase high performance liquid chromatographic (RP-
HPLC) method, for simultaneous determination of ritonavir (RIT), ombitasvir (OMB) and paritaprevir (PAR) in bulk mixtures, and in tablets. 
Methods: Determination of the drugs ritonavir (RIT), ombitasvir (OMB), and paritaprevir (PAR), was carried out applying Hypersil BDS C18 column 
(250 mm X 4.6 mm i.e., 5 µm particle size), with photodiode array detector at λmax
Results: Ritonavir, ombitasvir, and paritaprevir showed linearity of response between 12.5-75 μg/ml for ritonavir, 3.125-18.75 µg/ml for ombitas-
vir and 18.75–112.5 µg/ml for paritaprevir, with a correlation coefficient (R
 of 254 nm. The mobile phase applied for the current study composed 
of two solvents, i.e. A (0.01N % w/v potassium di-hydrogen orthophosphate buffer, pH 3.0 adjusted with dilute orthophosphoric acid) and B (acetoni-
trile). The mobile phase was pumped at a flow rate of 1.0 ml/min in the isocratic mode. The validation study with respect to specificity, linearity, preci-
sion, accuracy, and robustness, limit of detection (LOD) and limit of quantification (LOQ) was carried out employing the ICH guidelines. 
2
Conclusion: The method was successfully employed, for the quantification of RIT, OMB, and PAR, in the quality control of in-house developed tab-
lets, and can be applied for the industrial use. 
) 0.999, 0.999,0.999 for RIT, OMB, and PAR respectively. The % recov-
ery obtained was 99.82±0.14 % RIT, OMB 100.03±0.96 % and for 99.96±0.26 % PAR. The LOD and LOQ values for RIT, OMB, PAR were obtained to 
be 0.02, 0.019and0.02, µg/ml and 0.07, 0.06 and 0.07 µg/ml, respectively. The method also exhibits good robustness for different chromatographic 
conditions like wavelength, flow rate, mobile phase, and injection volume. 
Keywords: Ombitasvir, Ritonavir, Paritaprevir, RP-HPLC, ICH guidelines 




Ritonavir, [1] is chemically known as 2,4,7,12-tetra azatridecan-13-
oicacid, 10-hydroxy-2-methyl-5-(1-methyl ethyl)-1-[2-(1-methyl ethyl)-
4-thiazolyl]-3,6-dioxo-8,11-bis(phenylmethyl)-5-thiazolmethyl ester. It 
is an antiretroviral drug [2], an inhibitor of HIV-1 (human immunode-
ficiency virus) protease [3-5] used to treat HIV infection and 
AIDS (acquired immune deficiency syndrome). As of now once in a 
while utilized for its own particular antiviral movement [6], yet re-
mains generally utilized as a sponsor of other protease inhibitors. This 
prevents cleavage of the gag-pol polyprotein [7]. All the more particu-
larly, ritonavir is utilized to restrain a specific liver catalyst that ordi-
narily processes protease inhibitors, CYP3A4 is a member of 
the cytochrome P450 family of oxidizing enzymes [8]. Ombitasvir is an 
antiviral medication for the treatment of hepatitis C [9] infection 
(HCV) due to hepatitis C virus. In the United States, it is affirmed by the 
Food and Drug Administration for use in the blend with paritaprevir, 
ritonavir and dasabuvir in Viekira Pak for the treatment of HCV geno-
type 1 [10] and with paritaprevir and ritonavir in Technivie for the 
treatment of HCV genotype 4 [11]. Paritaprevir is an acyl sulfonamide 
inhibitor that shows promising outcomes for the treatment of hepatitis 
C [12]. At the point when given in mix with ritonavir and ribavirin for 
12 w, the rate of supported virological reaction at 24 w after treatment 
has been evaluated to be 95% for those with hepatitis C virus genotype 
1 [13]. Resistance to treatment with paritaprevir is phenomenal, on 
the grounds that it focuses on the coupling site, however, has been 
believed to emerge because of transformations at positions 155 and 
168 in NS3 [14]. Paritaprevir is available in three fixed-dose products: 
Viekira Pak (FDA), Technivie (FDA and Health Canada) and Holkira 
Pak (Health Canada) in Canada and the United States [15]. Different 
analytical methods are in like manner itemized in the written work for 
the estimation of ritonavir, ombitasvir and paritaprevir. As showed by 
composing study there is one specialized method for the estimation of 
ritonavir, ombitasvir and paritaprevir by RP-HPLC in tablet estimation 
[16, 17]. Thus, it has been proposed to make a method for estimation 
and endorsement of ritonavir, ombitasvir and paritaprevir in the ar-
rangement according to the ICH rules [18]. 
MATERIALS AND METHODS  
Instrumentation 
Chromatography was performed with Alliance waters 2695 HPLC, 
autosampler, section stove, degasser, 2996 PDA locator and class 
empower-2 software. 
Reagents and chemicals 
Acetonitrile (HPLC grade), orthophosphoric acid (HPLC grade) and 
water (HPLC grade) were purchased from Merck (India) Ltd, Worli, 
Mumbai, India. All active pharmaceutical ingredients (APIs) of rito-
navir, ombitasvir, and paritaprevir as reference standards were 
procured from Spectrum Pharma labs, Hyderabad, India. 
Chromatographic condition 
Chromatographic analysis was done using isocratic elution and by 
using acetonitrile and 0.01N potassium di-hydrogen phosphate, pH 
adjusted to 3.0 with OPA (65:35 by volume) as a mobile phase and was 
filtered through 0.45 μ membrane filter paper. The flow rate of mobile 
phase was monitored at 1 ml/min and eluents were detected at 254 
nm. Operating pressure 2400 psi was maintained at room temperature 
by injecting the volume 10 μl with a runtime 7 min. 
Preparation of standard solution  
Accurately weighed 50 mg of ritonavir, 12.5 mg of ombitasvir and 75 
mg of paritaprevir were taken and exchanged to three 100 ml volu-
metric flasks independently. 10 ml of methanol was added to flagons 
and sonicated for 15 min and then diluted to 1 ml of the above solu-
tion to 10 ml with the diluent. 
Preparation of sample solution  
5 tablets were weighed and calculated the average weight of each 
tablet. Then the weight equivalent to 1 tablet was transferred into a 
100 ml volumetric flask, 30 ml of diluent added and sonicated for 25 
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min, further, the volume made up with diluent and filtered. 1 ml of 
filtered sample stock solution was transferred to the 10 ml volume-
tric flask and made up with diluents.  
Validation  
The optimized chromatographic separation was aimed to obtain a 
resolution above 6.3 between all components, tailing factor is less 
than 2.0 and plate count will be more than 2000 with respect to the 
stationary, mobile phase compositions, flow rate, sample volume, 
detection wavelength and temperature. 
Validation procedure 
In the present method, validation was done with the aspect of sys-
tem suitability, specificity, accuracy, precision, linearity, robustness, 
limit of detection (LOD), limit of quantitation (LOQ), forced degrada-
tion and stability according to the ICH guidelines [19, 20]. 
 
 
Fig. 1: Typical chromatogram for ritonavir, ombitasvir and paritaprevir 
 
System suitability  
As per the test method, the standard solutions were prepared and 
injected into HPLC system, from which the evaluated system suita-
bility parameters were found to be within the limits [21, 22].  
Specificity  
The analyte was assessed unequivocally to know the components 
impurity which may be expected to be present with the help of spe-
cificity. As per test method blank was prepared and injected. No 
blank peak was eluted in the retention time of the analyte peak. 
Placebo solutions were prepared in duplicate and injected as per test 
method. It was found that no placebo peaks interfered at the reten-
tion time of the main peak [23].  
Accuracy  
Three different concentrations such as lower quantitation limit, 
medium quantitation limit, and higher quantitation limit were used 
to evaluate the accuracy of RP-HPLC method. The amount of drugs 
present, percentage recovery, and RSD were calculated by giving a 
minimum of three injections from each concentration.  
Precision  
The precision of test method was evaluated by considering six dif-
ferent concentrations. The amount of drugs present, percentage 
recovery, and RSD were calculated by giving a minimum of six prep-
arations. 
Linearity and range 
Six series of standard solutions were selected for assessing linearity 
range, by using peak area versus concentration of the standard solu-
tion. Calibration curve was plotted and the regression equations 
were also calculated. The slope, intercept and correlation coefficient 
were calculated by the least squares method. 
LOD and LOQ  
By using optimized chromatographic conditions in accordance with 
3.3 s/n and 10 s/n criteria, where s/n indicates signal-to-noise ratio, 
the LOD and LOQ were determined by injecting progressively lower 
concentrations of standard solutions into the HPLC column. 
Forced degradation 
In chromatogram of forced degradation there should be no interfe-
rence between peaks and were well separated from each other with 
the resolution at least 1.0 and peak purity of the principal peaks 
should pass. Forced degradation studies were performed by differ-
ent types of stress conditions to obtain the degradation of about 
20%.  
Robustness  
Small changes such as±10 % in the ratio of acetonitrile in the mobile 
phase,±0.1 ml/min in the flow rate and±5 °C in the temperature 
were made to demonstrate the robustness method. The separation 
factor, retention time and peak asymmetry were calculated.  
Stability  
Standard and the sample solutions were subjected to 24 h stability 
studies. The stability of these solutions was studied and observed for 
changes in the area and retention time of the peaks which were then 
compared with pattern of chromatogram of freshly prepared solution. 
Statistical analysis 
Wherever applicable, results were expressed as the mean±SD, % 
RSD and data were analyzed statistically by using t-test with aid of 
Microsoft Excel-2007 software and data was considered not signifi-
cantly different at 5 % significance level of probability P ≤0.05. 
RESULTS AND DISCUSSION 
Method development 
Initially, reverse phase liquid chromatography separation was tried to 
develop using various ratios of methanol and water, acetonitrile and 
water as mobile phases, in which drugs did not respond properly, and 
the resolution was also poor. The organic content of the mobile phase 
was also investigated to optimize the separation of both drugs. To 
improve the tailing factor, the pH of mobile phase becomes an impor-
tant factor. Hypersil BDS 250 mm x 4.6 mm, i.e. 5 µm with an isocrat-
ic mobile phase composed of 0.01N KH2PO4
10 µl of working standard solution (ritonavir 50 µg/ml, ombitasvir 
12.5 µg/ml and paritaprevir 75 µg/ml) was prepared and injected 
into the system. It was determined by making six replicate injections 
and all the parameters were found to be within the limits. The re-
sults were given in table 1. 
 buffer and acetonitrile 
(65:35A) at a flow rate of 1 ml/min. The column temperature was 
maintained at 30 °C and the detection was carried out using a PDA 
detector at 254 nm. The tailing of both peaks was reduced considera-
bly and brought close to 1. Drug detections were tried at wavelength 
254 nm. Ritonavir, ombitasvir and paritaprevir showed maximum 
absorption at 254 nm of wavelength and 254 nm was selected as the 
detection wavelength for PDA detector. The retention times were 
found to about 2.598 min, 3.491 min and 4.120 min for ritonavir, om-
bitasvir and paritaprevir. The chromatogram obtained was shown in 
the fig. 1 
Method validation 
System suitability and Specificity  
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Table 1: System suitability parameters for ritonavir, ombitasvir and paritaprevir 
S. No. Ritonavir Ombitasvir Paritaprevir 
Inj Rt(min) Tp Tailing Rt(min) Tp Tailing Rt(min) Tp Tailing 
1 2.568 6022 1.32 3.484 8244 1.11 4.104 8981 1.06 
2 2.571 6105 1.32 3.484 8272 1.09 4.106 9054 1.06 
3 2.574 6272 1.32 3.485 8284 1.09 4.107 9075 1.06 
4 2.581 6059 1.33 3.486 8706 1.09 4.111 9280 1.06 
5 2.588 6226 1.33 3.491 8432 1.05 4.117 9024 1.06 
6 2.598 5995 1.32 3.491 8461 1.1 4.12 8911 1.05 
 
Linearity 
The calibration curve was linear in the range of 12.5-75 μg/ml for 
ritonavir, 3.125-18.75 µg/ml for ombitasvir and 18.75-112.5 µg/ml 
for paritaprevir. These were represented in linear regression equa-
tion by as follows: y = 16942. x+543.0(R2=0.999) for ritonavir, 
y=29239.x+581.5(R2=0.999) for ombitasvir y= 33194.x+605.2 
R2=0.999) for paritaprevir and a regression line was established by 
the least squares method and correlation coefficient (R2
 
) for ritona-
vir, ombitasvir, and paritaprevir was found to be greater than 0.98. 
Hence the curves established were linear. The results were given in 
table 2. 
Table 2: Linearity data for ritonavir, ombitasvir and paritaprevir 
Ritonavir Ombitasvir Paritaprevir 
Conc (μg/ml) Peak area Conc (μg/ml) Peak area Conc (μg/ml) Peak area 
12.5 207143 3.125 93230 18.75 621771 
25 434680 6.25 185929 37.5 1252558 
37.5 632715 9.375 269148 56.25 1865441 
50 849226 12.5 365988 75 2474466 
62.5 1052389 15.625 460995 93.75 3132183 
75 1274858 18.75 547621 112.5 3728106 
Corr Coef  0.999 Corr Coef  0.999 Corr Coef  0.999 
Slope 16942 Slope 29239 Slope 33194 
Intercept 
 543.0 Intercept 




Fig. 2: Chromatogram for linearity-1 
 
 
Fig. 3: Chromatogram for linearity-2 
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Fig. 4: Chromatogram for linearity-3 
 
 
Fig. 5: Chromatogram for linearity-4 
 
 
Fig. 6: Chromatogram for linearity-5 
 
 
Fig. 7: Chromatogram for linearity-6 
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Fig. 8: Linearity plot for ritonavir 
 
 
Fig. 9: Linearity plot for ombitasvir 
 
 
Fig. 10: Linearity plot for paritaprevir, X
 
-axis = concentration, Y-axis = peak area 
Table 3: Accuracy data for ritonavir 
% Level  Amount spiked (μg/ml) Amount recovered (μg/ml) Area counts  % Recovery   Mean±SD 
50%  25 24.78 1267509 99.13 99.72, 
0.84 25  25.17  1274083 100.68 
25  24.84  1268467 99.36 
100%  50 50.48 1702847 100.96 100.18, 
0.68 50  49.85  1692222 99.70 
50  49.94  1693777 99.89 
150%  75 74.37 2107589 99.16 99.54, 
0.36 75  74.71  2113333 99.61 
75  74.89  2116459 99.86 
#SD: Standard deviation, result expressed in mean±SD and n=3 
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Table 4: Accuracy data for ombitasvir 
% Level  Amount spiked (μg/ml) Amount recovered (μg/ml) Area counts  % Recovery  Mean±SD 
50% 6.25 6.273 549483 100.37 99.95, 
0.39 6.25 6.244 548638 99.90 
6.25 6.224 548057 99.59 
100% 12.5 12.573 733683 100.58 100.33, 
0.68 12.5 12.606 734655 100.85 
12.5 12.445 729940 99.56 
150% 18.75 18.807 915981 100.31 99.80, 
0.64 18.75 18.754 914411 100.02 
18.75 18.579 909292 99.09 
 #
 
SD: Standard deviation, result expressed in mean±SD and n=3 
Table 5: Accuracy data for paritaprevir 
% Level  Amount spiked (μg/ml) Amount recovered (μg/ml) Area counts  % Recovery  Mean±SD 
50% 37.5 37.92 3748935 101.13 100.06 
0.92 37.5 37.36 3730192 99.62 
37.5 37.29 3728023 99.45 
100% 75 74.84 4974242 99.78 100.15, 
0.34 75 75.16 4985115 100.22 
75 75.34 4990947 100.45 
150% 112.5 111.57 6193620 99.17 99.66, 
0.52 112.5 112.74 6232462 100.21 
112.5 112.05 6209539 99.60 
#
 
SD: Standard deviation, result expressed in mean±SD and n=3 
 
Fig. 11: Chromatogram for accuracy 50%-1 
 
 
Fig. 12: Chromatogram for accuracy 50%-2 
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Fig. 13: Chromatogram for accuracy 50%-3 
 
 
Fig. 14: Chromatogram for accuracy 100%-1 
 
 
Fig. 15: Chromatogram for accuracy 100%-2 
 
 
Fig. 16: Chromatogram for accuracy 100%-3 
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Fig. 17: Chromatogram for accuracy 150%-1 
 
 
Fig. 18: Chromatogram for accuracy 150%-2 
 
 
Fig. 19: Chromatogram for accuracy 150%-3 
 
Table 6: Repeatability data for ritonavir, ombitasvir and paritaprevir 
S. No. Area of ritonavir n=6 Area of ombitasvir n=6 Area of paritaprevir n=6 
1. 853526 367465 2520129 
2. 863014 363235 2514709 
3. 862364 364103 2578495 
4. 851521 366719 2514428 
5. 856136 363687 2508742 
6. 852367 363628 2502558 
Mean 856488 364806 2523177 
SD 5053.1 1807.3 27753.0 




These results were within the acceptable limit of 98-102. The % 
RSD for ritonavir, ombitasvir and paritaprevir were 0.7, 1.0 and 
0.6 and it is within the limit of ≤2, hence the pr oposed method was 
accurate and the results were summarized in table 3, 4 and 5. 
Precision  
Repeatability 
n: number of injections (n=6), # %RSD: percent relative standard deviation 
The % RSD found to be 0.6, 0.5 and 1.1 respectively, the obtained 
results were within an acceptable limit of ≤2 and hence this m e-
thod was reproducible and the results were shown in table 6. 
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Table 7: Intermediate precision data for ritonavir, ombitasvir and paritaprevir 
S. No. Area of ritonavir n=6 Area of ombitasvir n=6 Area of paritaprevir n=6 
1. 848671 358194 2506847 
2. 857139 357744 2509322 
3. 847451 357290 2507333 
4. 848792 353484 2464440 
5. 852392 353117 2494836 
6. 850073 354121 2489685 
Mean 850753 355658 2495411 
SD 3550.0 2323.2 17080.7 
%RSD 0.4 0.7 0.7 
 #
 
n: number of injections (n=6), # %RSD: percent relative standard deviation 
 
Fig. 20: Chromatogram for method precision-1 
 
 
Fig. 21: Chromatogram for method precision-2 
 
 
Fig. 22: Chromatogram for method precision-3 
 
Intermediate precision  
The % RSD for ritonavir, ombitasvir and paritaprevir were found to 
be 0.4, 0.7 and 0.7 and it was within an acceptable limit of ≤2. 
Hence the method is reproducible on different days with different 
analyst and column. This indicates that the method was precise and 
the results were as shown in table 7. 
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Fig. 23: Chromatogram for method precision-4 
 
 
Fig. 24: Chromatogram for method precision-5 
 
 
Fig. 25: Chromatogram for method precision-6 
 
 
Fig. 26: Chromatogram for intermediate precision-1 
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Fig. 27: Chromatogram for intermediate precision-2 
 
 
Fig. 28: Chromatogram for intermediate precision-3 
 
 
Fig. 29: Chromatogram for intermediate precision-4 
 
 
Fig. 30: Chromatogram for intermediate precision-5 
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Fig. 31: Chromatogram for intermediate precision-6 
 
LOD and LOQ  
LOD and LOQ for ritonavir, ombitasvir and paritaprevir were 0.02, 
0.019and 0.02 μg/ml and 0.07, 0.06 and 0.07 μg/ml respectively. 
The lowest value of LOD and LOQ as obtained by the proposed me-
thod indicates that the method was sensitive [24]. 
 
Table 8: Results of LOD and LOQ 
Drug LOD(µg/ml) LOQ(µg/ml) 
Ritonavir 0.02 µg/ml 0.07 µg/ml 
Ombitasvir 0.019 µg/ml 0.06µg/ml 
Paritaprevir 0.02 µg/ml 0.07 µg/ml 
 #
 
LOD: limit of detection, # LOQ: limit of quantization 
 
Fig. 32: Chromatogram for LOD 
 
 
Fig. 33: Chromatogram for LOQ 
 
Degradation studies  
The degradation studies for ritonavir, ombitasvir and paritaprevir 
were performed by various conditions like acid, alkali, oxidation, 
thermal photolytic and neutral degradation and their limits like 
purity angle and purity threshold values were mentioned. It is ob-
served that the purity angle<purity threshold and the results were 
shown in table 9, 10 and 11.  
Oxidation 
To 1 ml of stock solution of ritonavir, ombitasvir, and paritaprevir, 1 
ml of 20 % hydrogen peroxide was added separately. The solutions 
were kept for 30 min at 60 °C. For HPLC study, the resultant solution 
was diluted to obtain 50 µg/ml, 12.5 µg/ml and 75 µg/ml solutions 
and 10 µl were injected into the system and the chromatograms 
were recorded to assess the stability of the sample. 
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Acid degradation studies 
1 ml of 2N Hydrochloric acid was added to 1 ml of stock solution of 
ritonavir, ombitasvir and paritaprevir. Then it was refluxed for 30 
min at 60 °C. The resultant solution was diluted to obtain 50 µg/ml, 
12.5 µg/ml and 75 µg/ml solutions and 10 µl solutions were injected 
into the system and the chromatograms were recorded to assess the 
stability of the sample. 
Alkali degradation studies 
To 1 ml of stock solution of ritonavir, ombitasvir and paritaprevir, 1 ml of 
2N sodium hydroxide was added and it was refluxed for 30 min at 60 °C. 
The resultant solution was diluted to obtain 50 µg/ml, 12.5 µg/ml and 75 
µg/ml solutions and 10 µl were injected into the system and the chroma-
tograms were recorded to know the stability of the sample. 
Dry heat degradation studies 
The standard drug solution was placed in an oven at 105 °C for 6 h to 
study dry heat degradation. For HPLC study, the resultant solutions 
was diluted to 150 µg/ml, 12.5 µg/ml and 75 µg/ml solution and10 
µl were injected into the system and the chromatograms were rec-
orded to measure the stability of the sample. 
Photo Stability studies 
The photochemical stability of the drug was also studied by exposing 
the 500 µg/ml, 125 µg/ml and 750 µg/ml solutions to UV light by 
keeping the beaker in UV Chamber for 7days or 200 Watt-hours/m2
Neutral degradation studies 
 
in photostability chamber. For HPLC study, the resultant solution 
was diluted to obtain 50 µg/ml, 12.5 µg/ml and 75 µg/ml solutions 
and 10 µl were injected into the system and the chromatograms 
were recorded in order to the stability of the sample. 
Stress testing under neutral conditions was studied by refluxing the 
drug in water for 6 h at a temperature of 60 °C. For HPLC study, the 
resultant solution was diluted to 50 µg/ml, 12.5 µg/ml and 75 µg/ml 
solutions and 10 µl were injected into the system and to assess the 
stability of the sample, the chromatograms were recorded. 
 
Table 9: Results of forced degradation studies of ritonavir 
S. No. Degradation condition % Drug degraded Purity angle Purity threshold 
1 Acid 4.00 0.199 0.346 
2 Alkali 2.58 0.165 0.310 
3 Oxidation 2.70 0.165 0.310 
4 Thermal 1.91 0.184 0.316 
5 UV 1.28 0.195 0.311 
6 Water 0.26 0.165 0.310 
 
Table 10: Results of forced degradation studies of ombitasvir
 
S. No. Degradation condition % Drug degraded Purity angle Purity threshold 
1 Acid 4.12 0.209 0.361 
2 Alkali 3.31 0.253 0.321 
3 Oxidation 3.26 0.253 0.321 
4 Thermal 2.33 0.259 0.345 
5 UV 1.87 0.175 0.327 
6 Water 0.56 0.253 0.321 
 
Table 11: Results of forced degradation studies of paritaprevir
 
S. No. Degradation condition % Drug degraded Purity angle Purity threshold 
1 Acid 3.97 0.103 0.303 
2 Alkali 2.81 0.106 0.302 
3 Oxidation 2.86 0.106 0.302 
4 Thermal 2.09 0.109 0.305 
5 UV 1.41 0.104 0.305 
6 Water 0.42 0.106 0.302 
 
 
Fig. 34: Chromatogram for acid degradation 
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Fig. 35: Chromatogram for base degradation 
 
 
Fig. 36: Chromatogram for peroxide degradation 
 
 
Fig. 37: Chromatogram for thermal degradation 
 
 
Fig. 38: Chromatogram for photolytic degradation 
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Fig. 39: Chromatogram for hydrolysis degradation 
 
Robustness  
It was observed that there was no marked change in mean Rt and % 
RSD was within a limit of ≤2. The tailing factor, resolution factor and 
no. of theoretical plates were found to be in acceptable limits for 
ritonavir, ombitasvir and paritaprevir. Hence this method was relia-
ble with variations in the analytical conditions and the results of 
ritonavir, ombitasvir and paritaprevir were shown in table 12. 
 
Table 12: Results for robustness 
S. No. Condition % RSD of ritonavir % RSD of ombitasvir % RSD of paritaprevir 
1 Flow rate (-) 0.9 ml/min 1.5 0.87 1.5 
2 Flow rate (+) 1.1 ml/min 0.2 1.4 0.1 
3 Mobile phase (-) 33B: 67A 0.7 0.79 0.6 
4 Mobile phase (+) 27B: 73A 1.0 1.0 1.1 
5 Temperature (-) 25 °C 1.1 1.3 1.1 
6 Temperature (+) 35 °C 1.2 0.64 0.6 
 
 
Fig. 40: Chromatogram for flow min 
 
 
Fig. 41: Chromatogram for flow plus 
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Fig. 42: Chromatogram for organic phase min 
 
 
Fig. 43: Chromatogram for organic phase plus 
 
 
Fig. 44: Chromatogram for temperature min 
 
 
Fig. 45: Chromatogram for temperature plus 
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Solution stability  
Sample solutions were analyzed initially for 24 h at different inter-
vals of time at room temperature and the results were recorded. The 
% deviation should not be more than 5.0 %. 
  
 
Fig. 46: Chromatogram for stability initial 
 
 
Fig. 47: Chromatogram for stability 24 h 
 
CONCLUSION 
Stability indicating RP-HPLC method was developed and validated for 
the simultaneous estimation of ritonavir, ombitasvir and paritaprevir 
in pharmaceutical formulations as per ICH guidelines. The developed 
method was found to be accurate, precise and reliable with % RSD less 
than 2 %. Therefore, the developed method was simple, accurate, 
precise and robust. The present method was found to be stability indi-
cating as the degradation of the drug substance was between 0.25-5 
percent. Finally, this method can be used for better analysis of phar-
maceutical formulations of ritonavir, ombitasvir and paritaprevir.  
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